Kexin Chen

Dr. Kexin Chen

orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
SLShengbiao Li
Shengbiao Li
YHYuping He
Yuping He
KCKexin Chen
Kexin Chen
JSJiaojiao Sun
Jiaojiao Sun
LZLulu Zhang
Lulu Zhang
QLQiuhong Li
Qiuhong Li
Glioblastoma, the most aggressive form of malignant glioma, is very difficult to treat because of its aggressively invasive nature and high recurrence rates. RAS‐selective lethal 3 (RSL3), a well‐known inhibitor of glutathione peroxidase 4 (GPX4), could effectively induce oxidative cell death in glioblastoma cells through ferroptosis, and several signaling pathways are involved in this process. However, the role of the nuclear factor kappa‐B (NF‐κB) pathway in glioblastoma cell ferroptosis has not yet been investigated. Therefore, we aimed to clarify the underlying mechanism of the NF‐κB pathway in RSL3‐induced ferroptosis in glioblastoma cells. We found that RSL3 led to an increase in lipid ROS concentration and downregulation of ferroptosis‐related proteins such as GPX4, ATF4, and SLC7A11 (xCT) in glioblastoma cells. Additionally, the NF‐κB pathway was activated by RSL3, and its inhibition by BAY 11‐7082 could alleviate ferroptosis. The murine xenograft tumor model indicated that NF‐κB pathway inhibition could mitigate the antitumor effects of RSL3 in vivo. Furthermore, we found that GPX4 knockdown could not effectively induce ferroptosis. However, NF‐κB pathway activation coupled with GPX4 silencing induced ferroptosis. Additionally, ATF4 and xCT expression might be regulated by the NF‐κB pathway. Collectively, our results revealed that the NF‐κB pathway plays a novel role in RSL3‐induced ferroptosis in glioblastoma cells and provides a new therapeutic strategy for glioblastoma treatment.

17 July 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
QLQiuhong Li
Qiuhong Li
KCKexin Chen
Kexin Chen
TZTianyi Zhang
Tianyi Zhang
DJDonghui Jiang
Donghui Jiang
LCLigang Chen
Ligang Chen
SLShengbiao Li
Shengbiao Li

7 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
KCKexin Chen
Kexin Chen
SWSi Wang
Si Wang
Age-related diseases such as cardiovascular disorders, neurodegeneration, and metabolic syndrome share a unifying pathological signature—persistent low-grade inflammation or “inflammaging”. Among the transcriptional regulators that orchestrate this process, RUNX1 has emerged as a pivotal molecular hub linking inflammation, cellular senescence, and tissue dysfunction. Traditionally recognized for its role in hematopoietic lineage specification, RUNX1 is now known to exert context-dependent regulatory functions across diverse organ systems. Its activation in aged tissues is driven by convergent pro-inflammatory and stress-related pathways—including NF-κB, MAPK, JAK/STAT, and oxidative signaling—that reinforce RUNX1 transcriptional activity through epigenetic reprogramming and chromatin remodeling. Sustained RUNX1 upregulation contributes to cellular senescence, fibrotic remodeling, and regenerative blockade, forming a self-perpetuating cycle of “inflammation amplification–functional decline”. In the cardiovascular, nervous, and hematopoietic systems, aberrant RUNX1 activation underlies fibrosis, neuroinflammation, and clonal hematopoiesis, respectively, establishing RUNX1 as a shared driver of age-associated pathology. The isoform-specific and temporally dynamic regulation of RUNX1 underpins its dual pro- and anti-inflammatory roles, highlighting its translational potential as both a biomarker and therapeutic target. A range of emerging intervention strategies has demonstrated promising capacity to precisely modulate RUNX1 activity. Collectively, these advances position RUNX1 at the intersection of inflammation, epigenetic instability, and tissue degeneration, opening new avenues for targeted intervention in inflammaging and age-related diseases.